Breaking News Headlines Today | Ground News

Black Friday Sale - Get 40% off Vantage

ajmc.com image

News from ajmc.com

ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

ajmc.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ajmc.com

Where is ajmc.com located?ajmc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ajmc.com News

Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (Onasemnogene ...

Pharma · United States

Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (Onasemnogene ...

60% Center coverage: 25 sources

New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), developed by Novartis, a major step forward for families living with spinal muscular atrophy…See the Story

Heat Waves Can Be Deadly for Seniors With Diabetes, Heart Disease

Veterans · Manassas

Heat Waves Can Be Deadly for Seniors With Diabetes, Heart Disease

55% Center coverage: 11 sources

Key Takeaways See the Story

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers - AstraZeneca (NASDAQ:AZN)

Cancer · United States

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers - AstraZeneca (NASDAQ:AZN)

100% Center coverage: 1 sources

FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.See the Story

Blindspots

NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says — REUTERS / ixx511

NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says — REUTERS / ixx511

NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says

Breaking News Topics Related to ajmc.com